Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 12 Buy, 2 Hold.
The consensus price target is $43.33 (low: $39.00, high: $51.00), representing an upside of 333.3% from the current price $10.00.
Analysts estimate Earnings Per Share (EPS) of $-4.36 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.68 vs est $-4.36 (beat +15.6%). 2025: actual $-5.90 vs est $-6.67 (beat +11.6%). Analyst accuracy: 84%.
CRBP Stock — 12-Month Price Forecast
$43.33
▲ +333.30% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Corbus Pharmaceuticals Holdings, Inc., the average price target is $43.33, with a high forecast of $51.00, and a low forecast of $39.00.
The average price target represents a +333.30% change from the last price of $10.00.
Highest Price Target
$51.00
Average Price Target
$43.33
Lowest Price Target
$39.00
CRBP Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to Corbus Pharmaceuticals Holdings, Inc. in the past 3 months
EPS Estimates — CRBP
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.68
vs Est –$4.36
▲ 18.5% off
2025
Actual –$5.90
vs Est –$6.67
▲ 13.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CRBP
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
